Journal
Haematologica
Publication Date
3-1-2025
Volume
110
Issue
3
First Page
706
Last Page
714
Document Type
Open Access Publication
DOI
10.3324/haematol.2024.285977
Rights and Permissions
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 1;110(3):706-714. doi: 10.3324/haematol.2024.285977. ©2025 Ferrata Storti Foundation Published under a CC BY-NC license.
Recommended Citation
Zelikson, Viktoriya; Amoozgar, Behzad; Kahl, Brad; and et al., "Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis from 21 US centers." Haematologica. 110, 3. 706 - 714. (2025).
https://digitalcommons.wustl.edu/oa_4/5026
Additional Links
Supplemental material is available for this article at publisher site.
